Skip to main content
SpringerLink
Log in

Therapeutic Value of Orphan Drugs Approved by Health Canada: A Cross-Sectional Study

  • Concise Research Report
  • Published:
Journal of General Internal Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Health Canada. Health products highlights 2021: helping you maintain and improve your health. Ottawa 2022 [updated August. Available from: https://www.canada.ca/content/dam/hc-sc/documents/services/publications/drugs-health-products/health-product-highlights-2021/health-product-highlights-2021-en.pdf.

  2. Patented Medicine Prices Review Board. Annual report 2021. Ottawa; 2022.

  3. Lexchin J. Quality and quantity of data used by Health Canada in approving new drugs. Frontiers in Medicine. 2023;10:1299239.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Lexchin J. Prediction of therapeutic value of new drugs approved by Health Canada from 2011-2020: a cross-sectional study. Journal of the Royal Society of Medicine Open. 2023;14(5).

  5. Chen E, Haslam A, Prasad V. FDA acceptance of surrogate end points for cancer drug approval. JAMA Internal Medicine. 2020;180(6):912-4.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Prasad V, Kim C, Burotto M, Vandross A. The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses. JAMA Internal Medicine. 2015;175(8):1389-98.

    Article  PubMed  Google Scholar 

  7. Dechartres A, Trinquart L, Boutron I, Ravaud P. Influence of trial sample size on treatment effect estimates: meta-epidemiological study. BMJ Open. 2013;346:f2304.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Health Policy and Management, York University, 4700 Keele St, Toronto, ON, M3J 1P3, Canada

    Joel Lexchin MD

  2. Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada

    Joel Lexchin MD

Authors
  1. Joel Lexchin MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joel Lexchin MD.

Ethics declarations

Conflict of Interest:

In 2020–2023, Joel Lexchin received payments for writing a brief on the role of promotion in generating prescriptions for Koski Minsky and from Strategy Institute for being on a panel discussing pharmacare. He is a member of the Board of Canadian Doctors for Medicare. He receives royalties from University of Toronto Press and James Lorimer & Co. Ltd. for books he has written. He is participating in projects funded by the Canadian Institutes of Health Research.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lexchin, J. Therapeutic Value of Orphan Drugs Approved by Health Canada: A Cross-Sectional Study. J GEN INTERN MED 39, 1276–1279 (2024). https://doi.org/10.1007/s11606-024-08651-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11606-024-08651-8

Search

Navigation